FDA Finally Hitting Sweet Spot With Off-Label Oversight
The U.S. Food and Drug Administration has slowly but surely eased Big Pharma's long-standing concerns about off-label marketing restrictions without antagonizing the plaintiffs bar or public health advocates....To view the full article, register now.
Already a subscriber? Click here to view full article